First clinical experiences with perampanel—The Kork experience in 74 patients

Abstract

Summary Perampanel (PER) has been approved for adjunctive treatment of partial‐onset seizures in patients age 12 years and older. In Germany, PER was licensed and marketed in September of 2012. At our tertiary referral epilepsy center, a couple of difficult‐to‐treat patients were awaiting this introduction of PER; therefore, we were able to initiate treatment in many patients within a short period of time. For this report we collected and analyzed the data of the first patients who had been started on add‐on PER between September and December of 2012, so that we were able to evaluate at least 6 months of treatment when we made this analysis. At cutoff in June of 2013, 74 patients could be analyzed. Mean age was 38.4 years (range 15–71 years). PER doses ranged from 4 to 14 mg (mean 8.8 mg). All patients took PER once daily at bedtime. Seventy‐one patients had focal epileptic seizures; the remaining four patients had Lennox‐Gastaut syndrome. Considering the last 3 months of observation compared with baseline, 34 patients (46%) were responders with a reduction of seizure frequency of at least 50%. Ten patients of these (14% of all) were seizure‐free. Adverse events were reported in 40 patients (54%). Leading side effects were somnolence (n = 31, 42%) and dizziness (n = 13, 18%), followed by ataxia, irritability, falls, cognitive slowing, and depression in single cases. Six‐month retention rate was 70%. Our first clinical experiences with add‐on PER in a highly selected group of difficult‐to‐treat epilepsies are promising.

Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data

“…Perampanel was well tolerated, with commonly expected AEs. The percentage of patients who were seizure free (27%) in the current study was slightly higher than that reported in other real-life studies: 14% in the single-centre German study and 15% in the multicentre study in Germany and Austria [Steinhoff et al 2014a[Steinhoff et al , 2014b.…”

“…Retention rates were high and similar among all three real-life studies (58% in our study versus 60% in the study in Germany and Austria, and 70% in the German study) [Steinhoff et al 2014a[Steinhoff et al , 2014b. Furthermore, retention has been shown to be highest (100%) in a real-life study using a very slow titration (<2 mg every 2 weeks) [Lawthom et al 2014].…”

“…The current study adds to the accumulating body of real-world data for perampanel, two studies of which have previously been published [Steinhoff et al 2014a[Steinhoff et al , 2014b. Perampanel was well tolerated and resulted in significant improvement of seizure control (50-100% reduction in seizures) in 42% of patients.…”

Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy

“…Observational studies reporting first "realworld" data in different patient populations with focal onset epilepsy have been recently published [56][57][58][59][60][61][62][63] with comparable results on efficacy and tolerability. In a paediatric cohort of 58 patients aged two to 17 years, first data on treatment response in patients with IGE (12 pts.)…”

Russian experience with perampanel in routine clinical practice

“…Steinhoff и соавт. [13], приступы не регистрировались в 14% случаев. Также подтвержден максимальный эффект при применении ПЕР в отношении ВГСП (исследования 304, 305, 306, 307) [10][11][12]14].…”